There is strong evidence that adalimumab increases risk of serious infections, such as tuberculosis.
It also increases the risk of cancers, including lymphoma and solid malignancies.
The risk of cancer is higher with higher doses of adalimumab.

There are rare reports of serious liver injury; rare reports of demyelinating central nervous system disorders; and rare reports of cardiac failure—the US Food and Drug Administration (FDA) issued a black box warning to doctors, which appears in the product labeling of adalimumab and other TNF-inhibiting drugs, instructing them to screen and monitor potential patients more carefully.
Anaphylaxis or other serious allergic reactions may also occur.
There is strong evidence that adalimumab increases risk of serious infections, such as tuberculosis. It also increases the risk of cancers, including lymphoma and solid malignancies. The risk of cancer is higher with higher doses of adalimumab.
There are rare reports of serious liver injury; rare reports of demyelinating central nervous system disorders; and rare reports of cardiac failure—the US Food and Drug Administration (FDA) issued a black box warning to doctors, which appears in the product labeling of adalimumab and other TNF-inhibiting drugs, instructing them to screen and monitor potential patients more carefully. Anaphylaxis or other serious allergic reactions may also occur.
Adalimumab